secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-258565
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru prices $25.2M public offering of common stock and warrants; net proceeds ~$23.4M for enobosarm study
--------------------------------------------------------------------------------

- Offering includes 1.4M common shares + 7M pre-funded warrants and 8.4M Series A and 8.4M Series B warrants at $3.00/unit.
- Gross proceeds expected ~$25.2M; net proceeds ~$23.4M after underwriting discounts and expenses.
- Closing expected on or about October 31, 2025, subject to customary conditions.
- Proceeds primarily to fund Phase 2b PLATEAU clinical study of enobosarm; also for working capital and general corporate purposes.
- Series A warrants expire 5 years from issuance; Series B warrants expire 3 years or upon meeting specific clinical milestones and stock price triggers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312525258565/0001193125-25-258565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312525258565/d59421d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-258565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer